



EUROPEAN PSYCHIATRIC ASSOCIATION



## **EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021**

### **SECTION COMMITTEE MEMBERS:**

Chairperson: Prof. István BITTER  
Co-chairperson: Prof. Julio BOBES  
Secretary: Prof. Matej Stuhec  
Councillor: Dr. Defne ERASLAN  
Councillor: Jonas EBERHARD

### **LAST SECTION COMMITTEE ELECTIONS HELD:**

Date: 2018  
Venue: Nice

### **ACTIVITIES OF THE SECTION IN 2021:**

#### **Meetings/events**

#### **Psychopharmacology During Infections, Including COVID-19**

##### **Description:**

Psychopharmacology During Infections, Including COVID-19

Proposed by the EPA Section on Psychopharmacology.

##### **Chairs:**

István Bitter, Hungary & Julio Bobes, Spain

##### **Speakers:**

1. The prevalence of comorbidity and mortality associated with infectious diseases in patients with psychiatric disorders. Presenter: István Bitter, Hungary
2. The challenges of psychopharmacological treatment during the COVID-19 pandemic in Lombardy. Presenter: Antonio Vita, Italy
3. The interactions between Covid-19 drugs and psychotropic agents.  
Presenter: Christoph Hiemke, Germany.



## **EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021**

4. The pharmacotherapy of infections in patients with mental disorders receiving psychotropic drugs: focus on good practices. Presenter: Matej Stuhec, Slovenia

**Location:** 29th European Congress of Psychiatry, EPA Virtual 2021, 10-13 April 2021

**Start date:** 11/04/2021

**End date:** 11/04/2021

### **Medication Deprescribing in Elderly Patients with Mental Disorders: Why, When, and How?**

#### **Description:**

Medication Deprescribing in Elderly Patients with Mental Disorders: Why, When, and How?

Proposed by the EPA Section on Old Age Psychiatry and EPA Section on Psychopharmacology

Chairs: Matej Stuhec, Slovenia & Gabriela Stoppe, Switzerland

1. Different General Strategies for Deprescribing in Real Clinical Settings: From Lists to Collaborative Care. Presenter M. Stuhec, Slovenia

2. Clinical Aspects of Deprescribing Process in Affective Disorders

Presenter. F. Bouckaert, Belgium

3. Deprescribing Process in Demented Patients: What Is the Rationale?

Presenter: G. Stoppe, Switzerland

4. Antipsychotics for Elderly with Psychosis: Deprescribe or Continue?

Presenter: P. Mohr, Czech Republic

**Location:** 29th European Congress of Psychiatry, EPA Virtual 2021, 10-13 April 2021

**Start date:** 13/04/2021

**End date:** 13/04/2021



## **EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021**

### **Psychopharmacology During Infections, Including COVID-19**

#### **Description:**

Session title: Symposium: Symposium: Psychopharmacology During Infections, Including COVID-19

Proposed by the EPA Section on Psychopharmacology.

#### **Chairs:**

Istvan Bitter, Hungary & Julio Bobes, Spain

#### **Speakers:**

1. The prevalence of comorbidity and mortality associated with infectious diseases in patients with psychiatric disorders. Presenter: Istvan Bitter, Hungary
2. The challenges of psychopharmacological treatment during the COVID-19 pandemic in Lombardy. Presenter: Antonio Vita, Italy
3. The interactions between Covid-19 drugs and psychotropic agents.  
Presenter: Christoph Hiemke, Germany.
4. The pharmacotherapy of infections in patients with mental disorders receiving psychotropic drugs: focus on good practices. Presenter: Matej Stuhec, Slovenia

**Location:** 29th European Congress of Psychiatry, EPA Virtual 2021, 10-13 April 2021

**Start date:** 11/04/2021

**End date:** 11/04/2021

### **Medication Deprescribing in Elderly Patients with Mental Disorders: Why, When, and How?**

#### **Description:**

Medication Deprescribing in Elderly Patients with Mental Disorders: Why, When, and How?

Chairs: Matej Stuhec, Slovenia & Gabriela Stoppe, Switzerland

#### **Speakers:**



## **EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021**

1. Different General Strategies for Deprescribing in Real Clinical Settings: From Lists to Collaborative Care. Presenter M. Stuhec, Slovenia

2. Clinical Aspects of Deprescribing Process in Affective Disorders

Presenter. F. Bouckaert, Belgium

3. Deprescribing Process in Demented Patients: What Is the Rationale?

Presenter: G. Stoppe, Switzerland

4. Antipsychotics for Elderly with Psychosis: Deprescribe or Continue?

Presenter: P. Mohr, Czech Republic

**Location:** 29th European Congress of Psychiatry, EPA Virtual 2021, 10-13 April 2021

**Start date:** 13/04/2021

**End date:** 13/04/2021

### **FUTURE ACTIVITIES:**

#### **Meetings/events**

#### **Psychotropic Drug Approvals Were Not Based on ICD-11: How to Treat Disorders Newly Defined in ICD-11?**

##### **Description:**

Chair(s)

Pavel Mohr (Czech Republic) István Bitter (Hungary)

1. ICD-11 Primary Psychotic Disorders: What is New and May be Relevant for Treatment Selection and Outcome? Presenter Wolfgang Gaebel (Germany)

2. Treating Catatonia: a Blind Spot of Psychiatry? Presenter Pavel Mohr (Czech Republic)

3. Neurodevelopmental Disorders in Adulthood: ADHD and ASD. Presenter J. Antoni R. QUIROGA (Spain)

4. Approved Indications vs. New Diagnostic Categories: Regulator's Point of View. Presenter Agnes Gyurasics (Hungary)



EUROPEAN PSYCHIATRIC ASSOCIATION



## **EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021**

**Location:** EPA Congress. The 30th European Congress of Psychiatry, 4-7 June 2022, Budapest (Hungary)

**Start date:** 04/06/2022

**End date:** 04/06/2022

### **Pharmacological Treatment of Elderly Patients with Comorbid Mental and Somatic Diseases**

#### **Description:**

Pharmacological Treatment of Elderly Patients with Comorbid Mental and Somatic Diseases, Sun, 05.06.2022

Chair(s)

Matej Stuhec (Slovenia) Cécile Hanon (France)

Organised by the EPA Sections on Old Age Psychiatry and Psychopharmacology.

1. Epidemiology and Pharmacoepidemiology of Comorbidities in Patients with Mental Disorders. Presenter István Bitter (Hungary)
2. General principles of pharmacotherapy selection in elderly patients for different comorbidities. Presenter Matej Stuhec (Slovenia)
3. Treatment of Insomnia in Multimorbid Elderly. Presenter Gabriela Stoppe (Switzerland)
4. Pain Medication in the Elderly Patient. Presenter Florian Riese (Switzerland)
5. Treatment of Somatic Comorbidities in the Elderly with Mental Disorders. Presenter Igor Filipcic (Croatia)

**Location:** EPA Congress. The 30th European Congress of Psychiatry, 4-7 June 2022, Budapest (Hungary)

**Start date:** 05/06/2022

**End date:** 05/06/2022

### **Psychopharmacology of Antipsychotics in Schizophrenia**

#### **Description:**

Psychopharmacology of Antipsychotics in Schizophrenia

EPA Course 11: Psychopharmacology of Antipsychotics in Schizophrenia



EUROPEAN PSYCHIATRIC ASSOCIATION



## EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021

Sun, 05.06.2022

Course Director: István Bitter, Hungary

Course Co-Director: Matej Stuhec, Slovenia

Organised by the EPA Section on Psychopharmacology.

This interactive, evidence-based course has been designed for early career psychiatrists, however other colleagues – especially those, who teach/supervise residents – also may benefit from the structured teaching material. The content of the course is primarily built on landmark studies and the data which will be discussed includes real world evidence as well. The participants should be able after completing the course to individually plan antipsychotic treatment for patients with schizophrenia and with some other psychotic disorders. The course will have a clinical focus and includes the following topics: • Short and long term treatment of schizophrenia with antipsychotics • Dose response relationship of antipsychotic drugs: How to define the right dose? Is there a therapeutic window? How do patients benefit from the use of therapeutic (plasma level) drug monitoring? • How to choose from different formulations of antipsychotics, e.g. different tablet forms, solution, rapid acting and long acting injectable (LAI) antipsychotics? • Comparative effectiveness of antipsychotics • Pharmacological treatment of negative symptoms in schizophrenia • The role of antipsychotics and other drugs in the management of agitation, suicidal and violent behavior in schizophrenia • Partial response, non – response and treatment resistance: Antipsychotic monotherapy vs. polypharmacy and the role of clozapine treatment • Possible treatment strategies to avoid antipsychotic polypharmacy • Length of antipsychotic treatment in schizophrenia; how to discontinue antipsychotic treatment; risks of antipsychotic withdrawal • Antipsychotic treatment in the elderly: schizophrenia and psychosis related to dementia • Management of the most frequent side effects and drug-drug interactions during treatment with antipsychotics.

**Location:** EPA Congress. The 30th European Congress of Psychiatry, 4-7 June 2022, Budapest (Hungary)

**Start date:** 05/06/2022

**End date:** 05/06/2022



EUROPEAN PSYCHIATRIC ASSOCIATION



## **EPA PSYCHOPHARMACOLOGY SECTION REPORT 2021 Publications**

**Mental Health Research and Practice: from evidence to experience. Psychopharmacology chapter – EPA.**

**Journal:**

Book Chapter, Cambridge University Press

**Authors:**

Authors: Pavel Mohr, Matej Stuhlec, István Bitter

**(Expected) Publication date:** 01/03/2022

**Acknowledged as official Section publication?** Yes

### **FUNDING IN 2021**

Income: None

Source(s) of funding:

None

Expenditure: None

Balance: None

EPA Treasurer audit: No

Confirmation that income / expenditure is via EPA: No